Burkitt S Lymphoma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for burkitt s lymphoma. 30 active patents protecting 2 drugs from 2+ originators. First major cliff: 2027. Daily refresh.

2
Approved drugs
30
Active US patents
48/100
Avg vulnerability
$1.0B
Annual revenue covered

Originators in Burkitt S Lymphoma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Baxter 15 patents Generic (originally Merck) 15 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating burkitt s lymphoma. Each bar = one year. Y-axis scaled to peak year (9 patents).

2
27
1
28
2
30
1
32
3
34
9
35
7
36
3
37
1
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cytoxan (Lyophilized)
cyclophosphamide
 Baxter 15 49 $1.0B 2035-06-26
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8101582 Decadron method of use 63 2027-12-19
7795316 Decadron method of use 63 2028-08-03
12150896 Decadron method of use 58 2036-10-07
12144889 Decadron method of use 58 2041-04-26
12329767 Cytoxan (Lyophilized) formulation 55 2036-02-15
12329767 Cytoxan (Lyophilized) formulation 55 2036-02-15
12329767 Cytoxan (Lyophilized) formulation 55 2036-02-15
11458041 Decadron method of use 53 2037-11-16
11304961 Decadron method of use 53 2037-12-18
11097061 Decadron method of use 53 2039-06-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
10799642 Decadron formulation 31 2032-05-11
8409606 Decadron formulation 31 2030-05-14
8450287 Decadron formulation 38 2027-12-19
10993952 Cytoxan (Lyophilized) formulation 42 2036-02-15
10993952 Cytoxan (Lyophilized) formulation 42 2036-02-15
9662342 Cytoxan (Lyophilized) formulation 42 2035-06-26
9662342 Cytoxan (Lyophilized) formulation 42 2035-06-26
10022502 Decadron method of use 45 2034-06-22

Related